M J Hauer

697 total citations
17 papers, 551 citations indexed

About

M J Hauer is a scholar working on Pharmacology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, M J Hauer has authored 17 papers receiving a total of 551 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pharmacology, 7 papers in Molecular Biology and 6 papers in Infectious Diseases. Recurrent topics in M J Hauer's work include Pharmacogenetics and Drug Metabolism (7 papers), HIV/AIDS drug development and treatment (5 papers) and HIV Research and Treatment (3 papers). M J Hauer is often cited by papers focused on Pharmacogenetics and Drug Metabolism (7 papers), HIV/AIDS drug development and treatment (5 papers) and HIV Research and Treatment (3 papers). M J Hauer collaborates with scholars based in United States and China. M J Hauer's co-authors include Larry C. Wienkers, Michael A. Wynalda, J. Matthew Hutzler, T. S. Tracy, Paul E. Fagerness, P E Sanders, J G Slatter, Kenneth L. Feenstra, James P. Sams and R.P. Stryd and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, Chemical Research in Toxicology and Drug Metabolism and Disposition.

In The Last Decade

M J Hauer

17 papers receiving 519 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M J Hauer United States 9 254 209 178 104 96 17 551
Edward J. Mroszczak United States 13 132 0.5× 360 1.7× 136 0.8× 101 1.0× 118 1.2× 26 794
Takayoshi Oguma Japan 13 210 0.8× 307 1.5× 127 0.7× 192 1.8× 106 1.1× 38 767
Aroonrut Lucksiri Thailand 11 71 0.3× 154 0.7× 119 0.7× 73 0.7× 41 0.4× 22 354
Roger D. Toothaker United States 14 79 0.3× 246 1.2× 94 0.5× 67 0.6× 102 1.1× 26 604
B. C. Jones United Kingdom 9 257 1.0× 136 0.7× 327 1.8× 149 1.4× 113 1.2× 10 646
Kimiko Tsutsumi Japan 14 50 0.2× 182 0.9× 180 1.0× 193 1.9× 118 1.2× 40 837
Satoshi Kishino Japan 16 232 0.9× 127 0.6× 108 0.6× 91 0.9× 197 2.1× 56 711
R.P. Stryd United States 9 199 0.8× 221 1.1× 37 0.2× 30 0.3× 69 0.7× 12 542
J G Slatter United States 6 193 0.8× 158 0.8× 41 0.2× 36 0.3× 64 0.7× 12 330
André J. Jackson United States 19 50 0.2× 165 0.8× 122 0.7× 102 1.0× 93 1.0× 46 800

Countries citing papers authored by M J Hauer

Since Specialization
Citations

This map shows the geographic impact of M J Hauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M J Hauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M J Hauer more than expected).

Fields of papers citing papers by M J Hauer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M J Hauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M J Hauer. The network helps show where M J Hauer may publish in the future.

Co-authorship network of co-authors of M J Hauer

This figure shows the co-authorship network connecting the top 25 collaborators of M J Hauer. A scholar is included among the top collaborators of M J Hauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M J Hauer. M J Hauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Slatter, J G, Dennis J. Stalker, Kenneth L. Feenstra, et al.. (2001). Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects.. PubMed. 29(8). 1136–45. 203 indexed citations
2.
Voorman, Richard, N A Payne, Larry C. Wienkers, M J Hauer, & P E Sanders. (2001). Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.. PubMed. 29(1). 41–7. 22 indexed citations
3.
Hutzler, J. Matthew, M J Hauer, & T. S. Tracy. (2001). Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model.. PubMed. 29(7). 1029–34. 81 indexed citations
4.
Wynalda, Michael A., M J Hauer, & Larry C. Wienkers. (2000). Oxidation of the Novel Oxazolidinone Antibiotic Linezolid in Human Liver Microsomes. Drug Metabolism and Disposition. 28(9). 1014–1017. 82 indexed citations
5.
Wienkers, Larry C., Cecilia Allievi, M J Hauer, & Michael A. Wynalda. (1999). Cytochrome P-450-Mediated Metabolism of the Individual Enantiomers of the Antidepressant Agent Reboxetine in Human Liver Microsomes. Drug Metabolism and Disposition. 27(11). 1334–1340. 46 indexed citations
6.
Sanders, P E, et al.. (1998). Quantitative analysis quantitation of 2-n-nonyl-1,3-dioxolane by stable-isotope dilution gas chromatography-mass spectrometry. Journal of Chromatography B Biomedical Sciences and Applications. 705(1). 39–45. 5 indexed citations
7.
Wienkers, Larry C., Rick C. Steenwyk, M J Hauer, Joseph C. Fleishaker, & Paul G. Pearson. (1998). Biotransformation of Tirilazad in Human: 3. Tirilazad A-Ring Reduction by Human Liver Microsomal 5α-Reductase Type 1 and Type 2. Journal of Pharmacology and Experimental Therapeutics. 287(2). 583–590. 3 indexed citations
8.
Wynalda, Michael A., M J Hauer, & Larry C. Wienkers. (1998). Human biotransformation of bropirimine. Characterization of the major bropirimine oxidative metabolites formed in vitro.. PubMed. 26(10). 1048–51. 5 indexed citations
9.
Wienkers, Larry C., Rick C. Steenwyk, M J Hauer, Joseph C. Fleishaker, & Paul G. Pearson. (1998). Biotransformation of tirilazad in human: 3. tirilazad A-ring reduction by human liver microsomal 5alpha-reductase type 1 and type 2.. PubMed. 287(2). 583–90. 7 indexed citations
10.
Voorman, Richard, et al.. (1998). Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A.. PubMed. 26(7). 631–9. 44 indexed citations
11.
Chang, Mayland, et al.. (1997). Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats.. PubMed. 25(2). 228–42. 12 indexed citations
12.
Slatter, J G, et al.. (1997). Metabolism of a bisphosphonate ester (PNU-91638) in rat. Xenobiotica. 27(10). 1039–1051. 2 indexed citations
13.
Chang, Mayland, et al.. (1997). Identification of the metabolites of the HIV-1 reverse transcriptase inhibitor delavirdine in monkeys.. PubMed. 25(7). 814–27. 11 indexed citations
14.
Chang, Mayland, G J Wilson, P E Sanders, et al.. (1997). Metabolism of the HIV-1 reverse transcriptase inhibitor delavirdine in mice.. PubMed. 25(7). 828–39. 10 indexed citations
15.
Slatter, J G, Kenneth L. Feenstra, M J Hauer, et al.. (1996). Metabolism of the bisphosphonate ester U-91502 in rats.. Drug Metabolism and Disposition. 24(1). 65–73. 7 indexed citations
16.
Koeplinger, Kenneth A., Gordon L. Bundy, Lee S. Banitt, et al.. (1996). In vitro and in vivo biotransformation of 6,7-dimethyl-2,4-di-1-pyrrolidinyl-7H-pyrrolo[2,3-D]pyrimidine (U-89843) in the rat.. Drug Metabolism and Disposition. 24(2). 187–198. 3 indexed citations
17.
Zhao, Zhiyang, Kenneth A. Koeplinger, Guy E. Padbury, et al.. (1996). Bioactivation of 6,7-Dimethyl-2,4-di-1-pyrrolidinyl-7H-pyrrolo[2,3-d]pyrimidine (U-89843) to Reactive Intermediates That Bind Covalently to Macromolecules and Produce Genotoxicity1. Chemical Research in Toxicology. 9(8). 1230–1239. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Edward J. Mroszczak Breakdown of academic impact, for papers by Takayoshi Oguma Breakdown of academic impact, for papers by Aroonrut Lucksiri Breakdown of academic impact, for papers by Roger D. Toothaker Breakdown of academic impact, for papers by B. C. Jones Breakdown of academic impact, for papers by Kimiko Tsutsumi Breakdown of academic impact, for papers by Satoshi Kishino Breakdown of academic impact, for papers by R.P. Stryd Breakdown of academic impact, for papers by J G Slatter Breakdown of academic impact, for papers by André J. Jackson
Rankless by CCL
2026